The novel role of the kidney in diabetes management: Sodium-glucose co-transporter 2 inhibitors

Metabolic Syndrome and Related Disorders

Volumn 13, Issue 7, 2015, Pages 287-291

  Swislocki, Arthur L M ^a,b   Jialal, Ishwarlal ^a,b  

^a VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

DIABETES MELLITUS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; KIDNEY FUNCTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; UNITED STATES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY; METABOLISM; URINARY EXCRETION; URINE;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; RENAL ELIMINATION; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84952059199     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2015.1504     Document Type: Review

References (40)

1. Sanford PA. The inhibition, and mechanism of intestinal absorption. Proc Nutr Soc 1967; 26: 12-17
2. Dimitrakoudis D, Vranic M, Klip A. Phlorizin mechanism: Effects of hyperglycemia on glucose transporters of the muscle: Use of the renal glucose reabsorption inhibitor phlorizin to control glycemia. J Am Soc Nephrol 1992; 3: 1078-1091
3. Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2014; 104: 297-322
4. Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: A review of their basic, and clinical pharmacology. Diabetes Ther 2014; 5: 355-366
5. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther 2014; 8: 1335-1380
6. Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: Progress, and therapeutic potential in type 2 diabetes mellitus. Drugs 2010; 70: 377-385
7. Pratley RE, Kuritzky L, Tenzer P. A patient-centered approach to managing patients with type 2 diabetes. Am J Med 2014; 127: e15-e16
8. Scheen AJ. Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucoselowering agents for the management of type 2 diabetes mellitus. Clin Pharmacokinet 2014; 53: 295-304
9. Scheen AJ. Pharmacodynamics, efficacy, and safety of sodiumglucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015; 75: 33-59
10. Scheen AJ, Paquot N. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence. Diabetes Metab 2014; 40(6 Suppl 1): S4-S11
11. Scheen AJ. Evaluating SGLT2 inhibitors for type 2 diabetes: Pharmacokinetic, and toxicological considerations. Expert Opin Drug Metab Toxicol 2014; 10: 647-663
12. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodiumglucose cotransporters for type 2 diabetes; A systematic review, and meta-analysis. Ann Intern Med 2013: 159: 262-274
13. Vivian EM. Sodium-glucose co-transporters: A growing class of antidiabetic agents. Drugs in Context 2014; 3: 3-19
14. Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications, and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 2014; 63: 1228-1237
15. Sha S, Polidori D, Farrell K, et al. Pharmacodynamic differences between canagliflozin, and dapagliflozin: Results of a randomized, double-blind, crossover study. Diabetes Obes Metab 2015; 17: 188-197
16. Truven Health Analytics. Available at https://www.micromedexsolutions.com/Accessed March 17, 2015
17. Macha S, Sennewald R, Rose P, et al. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther 2013; 35: 226-235
18. Macha S, Rose P, Mattheus M, et al. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab 2013; 15: 316-323
19. Bode B, Stenlöf K, Harris S, et al. Long-term efficacy, and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab 2015; 17: 294-303
20. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy, and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATASU): 52week results froma randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950
21. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012; 14: 539-545
22. Forst T, Guthrie R, Goldenberg R, et al. Efficacy, and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin, and pioglitazone. Diabetes Obes Metab 2014; 16: 467-477
23. Neal B, Perkovic V, De Zeeuw D, et al. Efficacy, and safety of canagliflozin, an inhibitor of sodium glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 2014; 38: 403-411
24. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial. Diabetes Care 2013; 36: 2508-2515
25. Stenlöf K, Cefalu WT, Kim K-A, et al. Efficacy, and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet, and exercise. Diabetes Obes Metab 2013; 15: 372-382
26. Yale JF, Bakris G, Cariou B, et al.; DIA3004 Study Group. Efficacy, and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus, and chronic kidney disease. Diabetes Obes Metab 2014; 16: 1016-1027
27. Yamout H, Perkovic V, Davies M, et al. Efficacy, and safety of canagliflozin in patients with type 2 diabetes, and stage 3 nephropathy. Am J Nephrol 2014; 40: 64-74
28. Yang XP, Lai D, Zhong XY, et al. Efficacy, and safety of canagliflozin in subjects with type 2 diabetes: Systematic review, and meta-analysis. Eur J Clin Pharmacol 2014; 70: 1149-1158
29. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2014; 38: 412-419
30. Nauck MA, Del Prato S, Durán-García S, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab 2014; 16: 1111-1120
31. Lewin AJ, Frías JP. Empagliflozin added to metformin, and sulfonylurea therapy in patients with sub-optimally controlled type 2 diabetes mellitus. Expert Opin Pharmacother 2015; 16: 781-784
32. McGill JB. The SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: A bench to bedside review. Diabetes Ther 2014; 5: 43-63
33. Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy, and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013; 15: 1154-1160
34. Häring HU, Merker L, Seewaldt-Becker E, et al.; EMPAREG MET Trial Investigators. Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014; 37: 1650-1659
35. Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin, and linagliptin in subjects with type 2 diabetes. Diabetes Care 2015; 38: 394-402
36. Ferrannini E, Berk A, Hantel S, et al. Long-term safety, and efficacy of empagliflozin, sitagliptin, and metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 2013; 36: 4015-4021
37. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin, and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015; 38: 384-393
38. Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy, and safety of empagliflozin for type 2 diabetes: A systematic review, and meta-analysis. Diabetes Obes Metab 2014; 16: 984-993
39. Rosenstock J, Jelaska A, Frappin G, et al.; EMPA-REG MDI Trial Investigators. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014; 37: 1815-1823
40. Scott LJ. Empagliflozin: A review of its use in patients with type 2 diabetes mellitus. Drugs 2014; 74: 1769-1784